 |
Ben Butkus is senior editor of GenomeWeb's premium content and the editor of PCR Insider. He covers technologies and trends in PCR, qPCR, nucleic acid amplification, and sample prep. E-mail Ben Butkus or follow his GenomeWeb Twitter account at @PCRInsider. |
Cepheid's Q1 Revenues Grow on Strong Clinical Reagent Sales; Analysts 'Unconcerned' with Net Loss
April 26, 2012
Cepheid's Q1 Revenues Grow on Strong Clinical Reagent Sales; Analysts 'Unconcerned' with Net Loss
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Cepheid Provides Update on MDx Pipeline with Focus on CT/NG, TB, Oncology
September 20, 2012 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - Dx Focus: Cepheid Xpert CT/NG; AITbiotech abTES Flu 4-Plex and MTB Real-Time Assays
January 3, 2013 / PCR Insider - Dx Focus: PEPFAR Funding Drives Cepheid TB Test Uptake; Curetis Starts US Trials for MDx System
December 6, 2012 / PCR Insider - Unitaid Provides $30M to Reduce Cost, Increase Uptake of Cepheid TB Test in Developing World
June 14, 2012 / PCR Insider